Brief: Sutro Biopharma FY Revenue USD 153.731 Million
25/03/2024 20:30
Mar 25 (Reuters) - Sutro Biopharma FY operating expenses USD 243.009 million. * FY operating income USD -89.278 million * FY basic EPS USD -1.78 * FY net income USD -106.793 million
Recent news on Sutro Biopharma
See all newsBrief: Sutro Biopharma Announces First Patient Dosed In Phase 1 Trial Of STRO-006
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Sutro Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary
Sutro Biopharma tumbles after missing estimates